Last updated on June 2019

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

Brief description of study

This randomized, active-controlled, multicenter, open-label, Phase III study is designed to investigate the efficacy and safety of alectinib compared with platinum-based in the adjuvant setting. Participants in the experimental arm will receive alectinib at 600 mg orally twice daily (BID) taken with food for 24 months.

Participants in the control arm will receive one of the protocol specified platinum based chemotherapy regimens for 4 cycles. Following treatment completion, participants will be followed up for their disease until disease recurrence. At the time of disease recurrence, participants will enter a survival follow-up until death, withdrawal of consent or study closure, whichever occurs earlier.

Clinical Study Identifier: NCT03456076

Find a site near you

Start Over

MGH Cancer Center

Boston, MA United States
  Connect »

University of Michigan

Ann Arbor, MI United States
  Connect »

Allegheny General Hospital

Pittsburgh, PA United States
  Connect »

Uni Hospital Mostar

Mostar, Bosnia and Herzegovina
  Connect »

CHU Angers

Angers, France
  Connect »

Private Health Organization Acibadem Sistina Hospital

Skopje, Macedonia, The Former Yugoslav Republic of
  Connect »

Townsville Hospital

Townsville, Australia
  Connect »

National Cancer Center

Gyeonggi-do, Korea, Republic of
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.